Clear Creek Financial Management, LLC Trevena Inc Transaction History

Clear Creek Financial Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 24, 2022	SELL	$0.16 - $100.0 $1,520 - $950,000	-9,500 Reduced 41.3%	13,500 $2,000
Q2 2022 Jul 27, 2022	SELL	$0.2 - $0.5 $3,800 - $9,500	-19,000 Reduced 45.24%	23,000 $10,000
Q1 2022 May 02, 2022	SELL	$0.41 - $0.63 $9,020 - $13,860	-22,000 Reduced 34.38%	42,000 $23,000
Q4 2021 Jan 21, 2022	SELL	$0.57 - $1.29 $1,994 - $4,515	-3,500 Reduced 5.19%	64,000 $37,000
Q3 2021 Oct 14, 2021	BUY	$1.11 - $1.7 $1,110 - $1,700	1,000 Added 1.5%	67,500 $83,000
Q2 2021 Jul 30, 2021	BUY	$1.46 - $2.25 $97,090 - $149,625	66,500 New	66,500 $112,000
Q1 2021 Apr 23, 2021	SELL	$1.77 - $2.93 $117,705 - $194,845	-66,500 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$2.13 - $3.26 $141,645 - $216,790	66,500 New	66,500 $142,000
Q3 2020 Nov 10, 2020	SELL	$1.53 - $3.13 $140,760 - $287,960	-92,000 Closed	0 $0
Q1 2020 Apr 23, 2020	BUY	$0.56 - $0.97 $1,960 - $3,395	3,500 Added 3.95%	92,000 $58,000
Q4 2019 Jan 17, 2020	BUY	$0.62 - $1.06 $1,240 - $2,120	2,000 Added 2.31%	88,500 $77,000
Q3 2019 Nov 15, 2019	BUY	$0.81 - $1.06 $10,530 - $13,780	13,000 Added 17.69%	86,500 $57,000
Q2 2019 Aug 16, 2019	BUY	$0.94 - $1.6 $69,090 - $117,600	73,500 New	73,500 $75,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of Clear Creek Financial Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Clear Creek Financial Management, LLC with notifications on news.